rTMS to Target Neural Connectivity and Rumination in Treatment-Resistant Depression
Eligible age
18–70 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to learn if Transcranial Magnetic Stimulation (TMS) to part of the brain called the ventromedial prefrontal cortex (VMPFC) can treat a symptom called rumination in adults with major depression that has not responded to at least one medication trial. The main question it aims to answer are: Does TMS to the VMPFC change brain activity on functional magnetic resonance imaging (fMRI) during a negative self-referential processing task in adults with depression? Does TMS to the VMPFC affect rumination in adults with depression? Researchers will compare brain scans and rumination scores before, during, and immediately after TMS. Participants will: Undergo three functional MRI scans Undergo a course of 20 TMS treatments Respond to clinical questionnaires and complete a computer behavioral task
Sponsor: Indiana University
You may qualify if…
- ✓ Diagnosis of unipolar major depressive disorder without psychotic features by the Mini-International Neuropsychiatric Interview (MINI) and confirmed by study psychiatrist
- ✓ First depressive episode prior to age 50
- ✓ Current moderate to severe depression, Hamilton Depression Rating Scale (HDRS) ≥17)
- ✓ Failure to respond to ≥1 antidepressant medication at adequate dose and duration in the current depressive episode; (note: this criterion is designed to be consistent with the original 2008 FDA-labeled indication for TMS in Major Depressive Disorder, that specifies failure to respond to "one prior medication at or above the minimal effective dose and duration in the current episode" (https://www.accessdata.fda.gov/cdrh\_docs/pdf8/K083538.pdf). ))
- ✓ Off psychotropic medications OR on a stable dose of medication(s) for 6 weeks, and willing to remain on stable medication dosage throughout the study
- ✓ Capacity to consent
- ✓ Ability to safely receive MRI
You may not qualify if…
- ✕ Actively/imminently suicidal, Quick Inventory of Depressive Symptomatology (QIDS) item 12 score \>2)
- ✕ Current depressive episode duration \> 5 years
- ✕ Presence of clinically significant psychiatric diagnoses other than unipolar, non-psychotic major depression, such as post-traumatic stress disorder (PTSD) or obsessive-compulsive disorder (OCD)
- ✕ Evidence of cognitive impairment, Montreal Cognitive Assessment (MOCA) \< 23)
- ✕ Significant substance use disorder within past 6 months
- ✕ New-onset psychotherapy and/or somatic therapy (e.g., light therapy) within 6 weeks of screening
- ✕ Prior exposure to any form of TMS
- ✕ Have participated in any clinical trial with an investigational drug or device within the past 6 weeks prior to screening
Where it's recruiting
Indianapolis
Source: ClinicalTrials.gov · NCT06511544 · last updated 2025-09-29